Plasmid News and Research

RSS

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

Vical Incorporated today announced that the company's Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company's herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).

27 Oct 2010

BioSilta releases EnPresso tablet that regulates protein production in recombinant bacteria

BioSilta announces the release of the EnPresso Tablet Cultivation Set, a tabletised form of the patented EnBase technology. The EnBase technology is based on providing an enzymatic-controlled glucose supply in a fed-batch type manner, which allows an extended growth period and promotes higher final cell density.

27 Oct 2010

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind Corporation today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma.

20 Oct 2010

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.

14 Oct 2010

GeoVax receives US Patent for pGA series of plasmids

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has been issued via an exclusive license from Emory University, a US Patent for its "DNA expression vectors and methods of use. Issued on September 14, 2010, the patent claims cover novel vectors and novel HIV vaccine inserts.

7 Oct 2010

Vical to manufacture pDNA vaccines against HIV

Vical Incorporated today announced that the company has agreed to manufacture plasmid DNA (pDNA) vaccines against HIV under a $2.4 million contract with the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).

7 Oct 2010

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced the award of a Fast Track SBIR from the Division of AIDS, National Institutes of Health for $3.1M to support the development of the Company's Transition State Vaccine (TSV) technology for a prophylactic HIV Vaccine.

6 Oct 2010

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that its unique Needle-Free Injection Therapy (NFIT) system, the Biojector 2000, is being utilized in a study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the U.S. National Institutes of Health (NIH).

29 Sep 2010

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.

29 Sep 2010

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics' Clean Genome E. coli. Financial details of the contract were not disclosed.

23 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

The U.S. Patent and Trademark Office has issued to Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled "Methods and Compositions for Immunotherapy of Cancer," based upon patent application 10/949,667.

10 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

Plasmid News and Research

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

New COLD-PCR technology to detect EGFR gene mutation

Vical to present preclinical results of HSV-2 vaccine program at Keystone Symposium

BioSilta releases EnPresso tablet that regulates protein production in recombinant bacteria

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

Top citations for scientific paper on Inovio's SynCon DNA vaccines and ID DNA delivery technology

GeoVax receives US Patent for pGA series of plasmids

Vical to manufacture pDNA vaccines against HIV

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

NIAID study utilizes Biojector B2000 system to explore syringe, needle benefits

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

RV262 Phase I study launched to evaluate DNA prime/MVA vector boost vaccine regimen for HIV

Scarab Genomics, Lonza enter sales agreement for Clean Genome technology

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

Tikcro reports $3.2 million net loss for second-quarter 2010

Vical second-quarter revenues decrease to $2.1 million

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News